U.S. pharma big copyright scrapped two experimental weight loss drugs very last year—a after-each day tablet, lotiglipron, as a result of elevated liver enzymes and a 2 times-day by day tablet, danuglipron, because of solid Negative effects—but CEO Albert Bourla has stated the company is set to “Perform and acquire” while in the obesity Are